Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This review discusses the potential applications of injectable platelet‐rich fibrin in various conditions and reports no new clinical results; the authors highlight its favorable use in comparison to existing treatments.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This study suggests that subtle modifications in ribosomal RNA methylation may influence cellular physiology and contribute to ribosome specialization in senescent human dermal fibroblasts.

This study reported that platelet-rich fibrin (iPRF) therapy may improve scalp health and hair appearance in women, showing beneficial changes in scalp hydration, redness, oiliness, and hair density, thickness, and loss.

This case study describes the successful use of recombinant feline interferon-omega in managing feline chronic gingivostomatitis syndrome in cats with type II diabetes, where long-acting corticosteroids are contraindicated.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This article discusses the financial independence of the International Society of Hair Restoration Surgery's forum and reports no new findings.

This study found that RXR-alpha is strongly expressed in both normal and psoriatic human skin, suggesting it may play a role in the transition from proliferation to differentiation in epidermal keratinocytes.

This study identified differentially expressed microRNAs between back and belly skin in Rex rabbits, highlighting their potential roles in skin development processes.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

This study found that overexpressing Rps14 in supporting cells promoted hair cell regeneration in the organ of Corti by facilitating cell proliferation and differentiation.

This study found that certain circulating miRNAs in skin and plasma may serve as potential biomarkers for distinguishing frontal fibrosing alopecia from control cases, highlighting the need for further validation in larger cohorts.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

In this study, RNA-sequencing identified differentially expressed genes, including FGF5, FGFR1, and RRAS, that affect the hair follicle growth cycle in Inner Mongolian Cashmere goats.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This study confirmed that an injectable implant known as RISUG-PH™, when administered via the vas deferens, successfully delivers the drug Finasteride to the prostate in male rats for up to 28 days, suggesting a potential localized alternative to oral delivery methods.

This study identified FP-1 as a highly specific extracellular matrix protein in follicular papilla cells, which may play a role in hair growth regulation during specific hair cycle phases.

This review discusses the role of noncoding RNAs (ncRNAs) in radiation response and highlights their potential as biomarkers for assessing radiation damage, but reports no new clinical results.

In this study, researchers found that the cell surface protein Lrig1 plays a crucial role in regulating the suppressive function of regulatory T cells, suggesting it as a potential target for treating autoimmune diseases, as evidenced by experiments in mouse models.

In this study, both radiofrequency microneedling and ultrasound treatments with a plant-based secretory factor hair serum enhanced hair and scalp health in subjects with androgenetic alopecia, with ultrasound showing more pronounced improvements in hair appearance, density, and color.

This study suggests that RCM may be a promising non-invasive diagnostic tool for alopecia areata incognita, showing substantial agreement with histopathology while noting some discrepancies.

In this study, researchers found that overexpression of LncRNA RP11-818O24.3 in hair follicle stem cells promotes their proliferation, self-renewal, and differentiation while inhibiting apoptosis through the FGF2-mediated PI3K/AKT signaling pathway, suggesting potential therapeutic applications for hair loss treatment.

This study found that three sessions of injectable platelet-rich fibrin (i-PRF+) significantly improved hair follicle density, hair volume, and thickness, as well as patient satisfaction in women with female pattern hair loss, with only minor self-limited adverse effects reported.